$ABBV News Microsoft, Amazon, Starbucks are st
Post# of 44962
Posted On: 05/05/2014 11:11:34 AM
$ABBV News
Microsoft, Amazon, Starbucks are stocks to watch 8:46 a.m. April 25, 2014 - Sue Chang
AbbVie shares rise after earnings top forecasts 8:10 a.m. April 25, 2014 - Ben Eisen
AbbVie shares rise 2.4% premarket on earnings 8:03 a.m. April 25, 2014 - Ben Eisen
Abbvie Q1 EPS tops forecast of $0.68 8:02 a.m. April 25, 2014 - Ben Eisen
AbbVie reaffirms 2014 adj EPS range of $3 to $3.10 8:00 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 sales rise to $4.56 bln vs $4.33 bln 8:00 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 EPS edges up to $0.61; Adjusted: $0.71 8:00 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 profit rises to $980 mln vs $968 mln 8:00 a.m. April 25, 2014 - Ben Eisen
I have no qualms about taking Gilead’s $84,000 drug 7:30 a.m. April 22, 2014 - Tim Mullaney
Long view on stocks is best during weak earnings season 6:00 a.m. April 20, 2014 - Wallace Witkowski
Abbott Labs profit falls 31% 8:45 a.m. April 16, 2014 - MarketWatch.com
First Solar tops S&P 500; Alcoa up ahead of earnings 3:52 p.m. April 8, 2014 - Sue Chang
Gilead: Hepatitis C Japan trial meets endpoint 3:44 a.m. April 3, 2014 - MarketWatch.com
Investors may need to go long if they hope to reap Baxter spinoff rewards 11:40 a.m. March 27, 2014 - Russ Britt
Jobs, winter weather to test record stock levels 7:02 a.m. March 2, 2014 - Wallace Witkowski
Analyst upgrades Gilead, says biotech is 'too good not to own' 3:06 p.m. Feb. 4, 2014 - Russ Britt
More positive tests for hep C drug boost AbbVie and Enanta shares 11:52 a.m. Jan. 31, 2014 - Russ Britt
Stock investors trash market darlings, face Apple, Fed 9:01 a.m. Jan. 26, 2014 - Wallace Witkowski
Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 4:09 p.m. Jan. 16, 2014 - Russ Britt
Investors warm up to Gilead's test results; shares climb 5% by close 5:49 p.m. Dec. 18, 2013 - Russ Britt
Finding Yield In Health Care 2:32 a.m. Today - Seeking Alpha
Two Big Pharma Picks to Buy Now 2:25 a.m. May 3, 2014 - Barrons.com
Medical Devices Face Onslaught Of Pricing Pressure 4:26 p.m. May 2, 2014 - Investors Business Daily
10 Healthcare Dogs Script 9% To 19% April Upsides 10:22 a.m. May 2, 2014 - Seeking Alpha
5 Weird & Unloved ETFs Getting The Job Done 7:05 a.m. May 2, 2014 - InvestorPlace.com
5 Biotech Stocks Ready To Resume Their Rally 5:08 p.m. May 1, 2014 - Barrons.com
MedTech's Partial Tax Repeal: Is It Enough? - Zacks Analyst Interviews 5:03 a.m. May 1, 2014 - Zacks.com
MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook 5:03 a.m. May 1, 2014 - Zacks.com
Repros Has an Edge on Auxilium 3:02 p.m. April 30, 2014 - Barrons.com
Momenta Pharmaceuticals Has Value In The Sum Of The Drugs 10:35 a.m. April 29, 2014 - Seeking Alpha
Stock Market News for April 29, 2014 - Market News 10:06 a.m. April 29, 2014 - Zacks.com
AbbVie Inc. (ABBV): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. April 28, 2014 - Zacks.com
Competition From AbbVie Will Not Hurt Gilead Sciences 10:07 p.m. April 27, 2014 - GuruFocus.com
Disappointments? Think Opportunities; Miracle Drug May Be Ailing Gilead: Jim Cramer's Best Blogs 6:00 a.m. April 26, 2014 - TheStreet.com
What's Developing at Lilly and AbbVie? 2:39 a.m. April 26, 2014 - Barrons.com
Is The Vanguard High Dividend Yield ETF Primed For Dividend Growth? 6:04 p.m. April 25, 2014 - Seeking Alpha
AbbVie Beats on Q1 Earnings, Humira Soars - Analyst Blog 4:45 p.m. April 25, 2014 - Zacks.com
AbbVie's CEO Discusses Q1 2014 Results - Earnings Call Transcript 2:43 p.m. April 25, 2014 - Seeking Alpha
AbbVie Beats Q1 Estimates, Downplays HCV 'Price War' 11:30 a.m. April 25, 2014 - Investors Business Daily
Why AbbVie (ABBV) Stock Is Higher This Morning 10:02 a.m. April 25, 2014 - TheStreet.com
Approvals from the European Commission and Release of Quarterly Financial Results - Analyst Notes on Merck, Johnson & Johnson, Bristol-Myers Squibb, Teva and AbbVie 8:00 a.m. May 2, 2014 - PR Newswire - PRF
Active Equities Technical Coverage -- Research on Mondelez Intl., Time Warner, AbbVie, and FireEye 4:40 a.m. May 1, 2014 - PR Newswire - PRF
Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014 3:10 p.m. April 28, 2014 - PR Newswire - PRF
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard 8:00 a.m. April 28, 2014 - PR Newswire - PRF
AbbVie Reports First-Quarter 2014 Financial Results 7:54 a.m. April 25, 2014 - PR Newswire - PRF
Stocks Close to Announcing their Earnings -- Research on AbbVie, Weyerhaeuser, Tyco Intl., and Colgate-Palmolive 5:11 a.m. April 25, 2014 - PR Newswire - PRF
Quarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie 8:00 a.m. April 24, 2014 - PR Newswire - PRF
AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C 8:46 a.m. April 22, 2014 - PR Newswire - PRF
Application Now Open for Students with Cystic Fibrosis for the 2014 AbbVie CF Scholarship 11:00 a.m. April 16, 2014 - PR Newswire - PRF
AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer 8:00 a.m. April 15, 2014 - PR Newswire - PRF
AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™ 1:00 a.m. April 12, 2014 - PR Newswire - PRF
Equities to Watch in the Health Care Sector -- Research on AbbVie, GlaxoSmithKline, AstraZeneca, and Novartis 9:46 a.m. April 9, 2014 - PR Newswire - PRF
AbbVie to Host First-Quarter Earnings Conference Call 8:00 a.m. April 7, 2014 - PR Newswire - PRF
Financial Results, Launches, Adjusted Conversion Rates, Upcoming Presentations, and Stock Movements - Analyst Notes on AbbVie, Chemed, Antares Pharma, Magellan Health Services, and Natus Medical 8:00 a.m. April 3, 2014 - PR Newswire - PRF
AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 International Liver Congress™ 5:00 a.m. March 24, 2014 - PR Newswire - PRF
Health Care Sector Equities Technical Commentary -- Research on AbbVie, GlaxoSmithKline, AstraZeneca and Novartis 6:44 p.m. March 21, 2014 - PR Newswire - PRF
AbbVie Initiates New Clinical Trial to Evaluate HUMIRA® (adalimumab) for the Treatment of Fingernail Psoriasis in Patients with Moderate to Severe Chronic Plaque Psoriasis 7:00 a.m. March 20, 2014 - PR Newswire - PRF
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE 8:00 a.m. March 14, 2014 - PR Newswire - PRF
AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections 3:30 p.m. March 3, 2014 - PR Newswire - PRF
AbbVie to Present at Barclays Global Healthcare Conference 2014 8:00 a.m. Feb. 26, 2014 - PR Newswire - PRF
Microsoft, Amazon, Starbucks are stocks to watch 8:46 a.m. April 25, 2014 - Sue Chang
AbbVie shares rise after earnings top forecasts 8:10 a.m. April 25, 2014 - Ben Eisen
AbbVie shares rise 2.4% premarket on earnings 8:03 a.m. April 25, 2014 - Ben Eisen
Abbvie Q1 EPS tops forecast of $0.68 8:02 a.m. April 25, 2014 - Ben Eisen
AbbVie reaffirms 2014 adj EPS range of $3 to $3.10 8:00 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 sales rise to $4.56 bln vs $4.33 bln 8:00 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 EPS edges up to $0.61; Adjusted: $0.71 8:00 a.m. April 25, 2014 - Ben Eisen
AbbVie Q1 profit rises to $980 mln vs $968 mln 8:00 a.m. April 25, 2014 - Ben Eisen
I have no qualms about taking Gilead’s $84,000 drug 7:30 a.m. April 22, 2014 - Tim Mullaney
Long view on stocks is best during weak earnings season 6:00 a.m. April 20, 2014 - Wallace Witkowski
Abbott Labs profit falls 31% 8:45 a.m. April 16, 2014 - MarketWatch.com
First Solar tops S&P 500; Alcoa up ahead of earnings 3:52 p.m. April 8, 2014 - Sue Chang
Gilead: Hepatitis C Japan trial meets endpoint 3:44 a.m. April 3, 2014 - MarketWatch.com
Investors may need to go long if they hope to reap Baxter spinoff rewards 11:40 a.m. March 27, 2014 - Russ Britt
Jobs, winter weather to test record stock levels 7:02 a.m. March 2, 2014 - Wallace Witkowski
Analyst upgrades Gilead, says biotech is 'too good not to own' 3:06 p.m. Feb. 4, 2014 - Russ Britt
More positive tests for hep C drug boost AbbVie and Enanta shares 11:52 a.m. Jan. 31, 2014 - Russ Britt
Stock investors trash market darlings, face Apple, Fed 9:01 a.m. Jan. 26, 2014 - Wallace Witkowski
Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 4:09 p.m. Jan. 16, 2014 - Russ Britt
Investors warm up to Gilead's test results; shares climb 5% by close 5:49 p.m. Dec. 18, 2013 - Russ Britt
Finding Yield In Health Care 2:32 a.m. Today - Seeking Alpha
Two Big Pharma Picks to Buy Now 2:25 a.m. May 3, 2014 - Barrons.com
Medical Devices Face Onslaught Of Pricing Pressure 4:26 p.m. May 2, 2014 - Investors Business Daily
10 Healthcare Dogs Script 9% To 19% April Upsides 10:22 a.m. May 2, 2014 - Seeking Alpha
5 Weird & Unloved ETFs Getting The Job Done 7:05 a.m. May 2, 2014 - InvestorPlace.com
5 Biotech Stocks Ready To Resume Their Rally 5:08 p.m. May 1, 2014 - Barrons.com
MedTech's Partial Tax Repeal: Is It Enough? - Zacks Analyst Interviews 5:03 a.m. May 1, 2014 - Zacks.com
MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook 5:03 a.m. May 1, 2014 - Zacks.com
Repros Has an Edge on Auxilium 3:02 p.m. April 30, 2014 - Barrons.com
Momenta Pharmaceuticals Has Value In The Sum Of The Drugs 10:35 a.m. April 29, 2014 - Seeking Alpha
Stock Market News for April 29, 2014 - Market News 10:06 a.m. April 29, 2014 - Zacks.com
AbbVie Inc. (ABBV): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. April 28, 2014 - Zacks.com
Competition From AbbVie Will Not Hurt Gilead Sciences 10:07 p.m. April 27, 2014 - GuruFocus.com
Disappointments? Think Opportunities; Miracle Drug May Be Ailing Gilead: Jim Cramer's Best Blogs 6:00 a.m. April 26, 2014 - TheStreet.com
What's Developing at Lilly and AbbVie? 2:39 a.m. April 26, 2014 - Barrons.com
Is The Vanguard High Dividend Yield ETF Primed For Dividend Growth? 6:04 p.m. April 25, 2014 - Seeking Alpha
AbbVie Beats on Q1 Earnings, Humira Soars - Analyst Blog 4:45 p.m. April 25, 2014 - Zacks.com
AbbVie's CEO Discusses Q1 2014 Results - Earnings Call Transcript 2:43 p.m. April 25, 2014 - Seeking Alpha
AbbVie Beats Q1 Estimates, Downplays HCV 'Price War' 11:30 a.m. April 25, 2014 - Investors Business Daily
Why AbbVie (ABBV) Stock Is Higher This Morning 10:02 a.m. April 25, 2014 - TheStreet.com
Approvals from the European Commission and Release of Quarterly Financial Results - Analyst Notes on Merck, Johnson & Johnson, Bristol-Myers Squibb, Teva and AbbVie 8:00 a.m. May 2, 2014 - PR Newswire - PRF
Active Equities Technical Coverage -- Research on Mondelez Intl., Time Warner, AbbVie, and FireEye 4:40 a.m. May 1, 2014 - PR Newswire - PRF
Metastatic Ovarian Cancer Global Clinical Trials Review, H1, 2014 3:10 p.m. April 28, 2014 - PR Newswire - PRF
Strategic Collaborations, Fresh Agreements, and Upcoming Conferences - Analyst Notes on Biogen, Bristol-Myers, AbbVie, Actavis and Bard 8:00 a.m. April 28, 2014 - PR Newswire - PRF
AbbVie Reports First-Quarter 2014 Financial Results 7:54 a.m. April 25, 2014 - PR Newswire - PRF
Stocks Close to Announcing their Earnings -- Research on AbbVie, Weyerhaeuser, Tyco Intl., and Colgate-Palmolive 5:11 a.m. April 25, 2014 - PR Newswire - PRF
Quarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie 8:00 a.m. April 24, 2014 - PR Newswire - PRF
AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C 8:46 a.m. April 22, 2014 - PR Newswire - PRF
Application Now Open for Students with Cystic Fibrosis for the 2014 AbbVie CF Scholarship 11:00 a.m. April 16, 2014 - PR Newswire - PRF
AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Patients with Non-Small Cell Lung Cancer 8:00 a.m. April 15, 2014 - PR Newswire - PRF
AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™ 1:00 a.m. April 12, 2014 - PR Newswire - PRF
Equities to Watch in the Health Care Sector -- Research on AbbVie, GlaxoSmithKline, AstraZeneca, and Novartis 9:46 a.m. April 9, 2014 - PR Newswire - PRF
AbbVie to Host First-Quarter Earnings Conference Call 8:00 a.m. April 7, 2014 - PR Newswire - PRF
Financial Results, Launches, Adjusted Conversion Rates, Upcoming Presentations, and Stock Movements - Analyst Notes on AbbVie, Chemed, Antares Pharma, Magellan Health Services, and Natus Medical 8:00 a.m. April 3, 2014 - PR Newswire - PRF
AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 International Liver Congress™ 5:00 a.m. March 24, 2014 - PR Newswire - PRF
Health Care Sector Equities Technical Commentary -- Research on AbbVie, GlaxoSmithKline, AstraZeneca and Novartis 6:44 p.m. March 21, 2014 - PR Newswire - PRF
AbbVie Initiates New Clinical Trial to Evaluate HUMIRA® (adalimumab) for the Treatment of Fingernail Psoriasis in Patients with Moderate to Severe Chronic Plaque Psoriasis 7:00 a.m. March 20, 2014 - PR Newswire - PRF
Investment Grants, Data Presentations, Clinical Study Results, and Collaborative Programs - Analyst Notes on UnitedHealth Group, Bristol-Myers Squibb, AbbVie, Cigna, and OXiGENE 8:00 a.m. March 14, 2014 - PR Newswire - PRF
AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections 3:30 p.m. March 3, 2014 - PR Newswire - PRF
AbbVie to Present at Barclays Global Healthcare Conference 2014 8:00 a.m. Feb. 26, 2014 - PR Newswire - PRF
(0)
(0)